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Abstract
Objective To determine whether women with atrial fibrillation have a
higher risk of stroke than men.
Design Nationwide retrospective cohort study.
Setting Patients with a diagnosis of atrial fibrillation in the Swedish
hospital discharge register between 1 July 2005 and 31 December 2008.
Information about drug treatment taken from the Swedish drug register.
Participants 100 802 patients with atrial fibrillation at any Swedish
hospital or hospital affiliated outpatient clinic with a total follow-up of 139
504 years at risk (median 1.2 years). We excluded patients with warfarin
at baseline, mitral stenosis, previous valvular surgery, or who died within
14 days from baseline.
Main outcome measure Incidence of ischaemic stroke.
Results Ischaemic strokes were more common in women than in men
(6.2% v 4.2% per year, P<0.0001). The univariable hazard ratio for
women compared with men was 1.47 (95% confidence 1.40 to 1.54),
indicating a 47% higher incidence of ischaemic stroke in women than
in men. Stratification according to the CHADS2 scheme showed increased
stroke rates for women in all strata. After multivariable adjustment for
35 cofactors for stroke, an increased risk of stroke in women remained
(1.18, 1.12 to 1.24). Among patients with “lone atrial fibrillation” (age
<65 years and no vascular disease), the annual stroke rate tended to
be higher in women than in men, although this difference was not
significant (0.7% v 0.5%, P=0.09). When low risk patients with CHADS2
scores of 0-1 were stratified according to their CHA2DS2-VASc scores,
women did not have higher stroke incidence than men at CHA2DS2-VASc
scores of 2 or less.
Conclusion Women with atrial fibrillation have a moderately increased
risk of stroke compared with men, and thus, female sex should be
considered when making decisions about anticoagulation treatment.
However, women younger than 65 years and without other risk factors
have a low risk for stroke, and do not need anticoagulant treatment.
Introduction
Severalstudieshaveindicatedthatwomenwithatrialfibrillation
areathigherriskofischaemicstrokethanmen,
1-6althoughother
studies have found no difference.
3 7 8 The systematic review of
stroke risk factors by the Stroke in Atrial Fibrillation Working
Group concluded that female sex multiplied the risk of stroke
by 1.6-fold, and female sex has been incorporated into stroke
risk assessment guidelines.
9 10
Differences in stroke risk between the sexes is of clinical
relevance, and of great practical importance if few or no other
strokeriskfactorsexist,andadecisionregardinganticoagulation
treatment is needed. It is also important to determine whether
the generally recognised risk factors for stroke are equally
important for men and women—that is, whether one common
scheme for stroke risk stratification can be used for men and
womenwithatrialfibrillation,oreachsexshouldhavedifferent
schemes.
The recent European Society of Cardiology guidelines
recommendtheuseoftheCHA2DS2-VAScscoretorefinestroke
risk stratification, and female sex carries one point on this
score.
10 The guidelines clearly recommend that antithrombotic
treatmentisnecessaryinallpatientswithatrialfibrillationunless
they are “age <65 and low risk.” However, this point is still
commonlymisinterpretedforwomenwithatrialfibrillationwho
areyoungerthan65yearsanddonothaveanyotherriskfactors
(that is, they still have a CHA2DS2-VASc score of 1), in that
theyshouldbetreatedwith“eitheroralanticoagulantsoraspirin
75-325 mg daily, with oral anticoagulants preferred rather than
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Research
RESEARCHaspirin.”Indeed,shoulddoctorsrecommendaphysicallyactive
woman aged, for example, 45 years with atrial fibrillation (and
no other risk factors) to take oral anticoagulants to avoid stroke,
while recommend a man under the same circumstances to have
no antithrombotic treatment? Furthermore, there remains
uncertainty about whether the term “lone atrial fibrillation” is
relevant in women, since their sex is considered a stroke risk
factor.Atapragmaticlevel,youngwomenwithatrialfibrillation
with female sex as the only risk factor (CHA2DS2-VASc score
1) should not need anticoagulation treatment, if they fulfil the
criteria of “age <65 and lone atrial fibrillation.”
10
Unfortunately, the studies on which we base these decisions do
not have much to say about such management situations,
although they are commonly encountered in clinical practice.
In a recent systematic review of stroke risk factors in atrial
fibrillation, as part of the guidelines from the UK National
InstituteforHealthandClinicalExcellence(NICE),
3fivestudies
showed higher stroke risk in women than in men, whereas six
other studies showed no difference in risk. The studies that did
not find an excess risk for women were generally smaller than
the studies that found increased risks for women and thus, the
negative studies could have been underpowered to show a
difference. The largest of these studies was the anticoagulation
and risk factors in atrial fibrillation (ATRIA) cohort study
1 of
13599patients,whichshowedahigherriskforischaemicstroke
inwomenthaninmen(hazardratio1.5,95%confidenceinterval
1.2 to 1.8). Furthermore, the NICE guidelines concluded that
although female sex could be a stroke risk factor, there was no
clear biological plausibility for this; therefore, female sex was
not included in NICE’s assessment algorithm for stroke risk.
11
In a nationwide retrospective cohort study, we aimed to
determine whether women with atrial fibrillation have a higher
risk of stroke than men with atrial fibrillation.
Methods
We used the Swedish national discharge register to identify all
individuals with a diagnosis for atrial fibrillation using code
I489oftheICD-10(internationalclassificationofdiseases,10th
revision; with or without subcodes A-F) between 1 July 2005
and 31 December 2008. This register contains records of all
hospital admissions and all visits to hospital outpatient clinics
for all patients with a Swedish civic registration number since
1987.
In the register, each hospital contact is recorded with one
principal diagnosis and up to nine ancillary diagnoses, and up
to 13 codes for surgical and other procedures. We used the
register to obtain information about comorbidities as well as
about events during follow-up. For current and previous
diseases, we considered admissions from 1997 onwards (that
is, from the year ICD-10 was implemented in Sweden). The
webappendixdefinestheICD-10codesusedtodefineendpoints
and comorbidities (table w1).
We used both principal and secondary diagnoses, and the web
appendix specifies the codes used for disease definitions. The
register does not include information about principal diagnoses
in0.5-0.9%ofadmissionsinsomaticcare.
12Adiagnosisofatrial
fibrillation or flutter in the register has a positive predictive
value of 97%.
13 The register’s validity is evaluated annually,
and is considered to be well suited for epidemiological studies
by the National Board of Health and Welfare.
14
We calculated each patient’s stroke risk score according to the
CHADS2 scheme. This score gives two points for a previous
stroke, transient ischaemic attack, or systemic emboli, and one
point each for heart failure, hypertension, diabetes, and age of
75 years or older.
15 We also calculated the newer
CHA2DS2-VASc score that, in addition to the CHADS2 score,
givestwopointsforageof75yearsorolder,andonepointeach
for age 65-74 years, vascular disease, and female sex.
2 10
The index date was when the patient was first diagnosed with
atrial fibrillation after 1 July 2005. For the registration of events
during follow-up, we applied a “blanking period” of 14 days
after index. We used this period because transfers between
hospitals and clinics were common, and early reappearances of
a diagnosis were often closely related to a preceding hospital
period—for example, a new code for an event that had been
registered at another clinic a few days earlier. Diagnoses given
on the index date and up to two weeks after that date were
considered as reflecting comorbidity, and were not counted as
endpoints during follow-up. Exclusion criteria were use of
warfarin at baseline, death in conjunction with the index
generatinghospitalperiod,mitralstenosis,orhistoryofvalvular
surgery.
We obtained drug information from Anatomical Therapeutic
Chemical classification codes in the national prescribed drugs
register. This register has automatically stored detailed
informationabouteverypharmacyprescriptioninSwedensince
1 July 2005; therefore, we regarded this register to be almost
100% complete. Drugs used at baseline were those that had
been collected at a pharmacy within 90 days of the index date.
The only registered oral anticoagulant in Sweden during the
study period was warfarin, with phenprocoumon used as an
alternativeonspeciallicensefortheveryfewpatientswhowere
intolerant to warfarin.
Statistical analysis
We presented baseline characteristics descriptively, and tested
differences between men and women with the t and χ
2 test.
Annual incidence of stroke was calculated as events per 100
years at risk, with results expressed as percentages, and tested
with Fisher’s exact test. We used the Taylor series method to
calculate95%confidenceintervals.Populationattributablerisk
(%) was calculated as (Ipopulation−Imen)/Ipopulation×100, where I is the
yearly incidence of stroke (number of events/years at risk). We
presentedsurvivalgraphicallyusingtheKaplan-Meiermethod,
and analysed rates using univariable and several multivariable
Cox regressions using the Efron method of handling ties. In the
multivariable models, we included comorbidities and use of
drugs that had known associations with stroke, bleeding, or
mortality (35 cofactors in total; table 1⇓). Censoring was done
at the earlier date of death or end of follow-up (31 December
2008).Primaryanalysiswasdonebyintentiontotreat,andonly
included baseline variables, but a Cox regression was also
estimated, which included exposure to acetylsalicylic acid,
clopidogrel, and warfarin as time dependent variables.
Foracetylsalicyclicacidandclopidogrel,weusedtheprescribed
doseandthequantityofpurchaseddrugstocalculatethenumber
ofdayseachprescriptionwouldlast,andmeasuredtheexposed
periodfromthedateofpurchase.Forwarfarin,sincedosevaries
both among individuals and over time, we estimated each
purchasetolastthreemonths.Weestimatedthisperiodbecause
aregulationinSwedenrequiresphysiciansnottoprescribemore
drugs than necessary for three months at a time (doctors may
prescribe four three-month periods on the same occasion, but
the patient can not claim it all at once). We disregarded gaps of
atleast90daysbetweendrugperiods,andconsideredthepatient
to be on continuous drug treatment.
Interactions between all variables and sex were tested for the
multivariable model, and selected interactions were presented
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renders similar interpretation, as if separate Cox regressions
had been performed on subgroups but with the additional
advantage of testing for differences between subgroups. We
investigatedthescaledSchoenfeldresidualsand“dfbetas”from
the primary model for violations to the proportional hazards
assumption and possible outliers, respectively, but detected no
problems.Thelinearassociationbetweenageandoutcomewas
investigated for the Martingale residuals and found to be
acceptable, but for the sensitivity analysis, age was also
modelled using restricted cubic splines.
We considered P<0.05 to be significant. Analyses were
performed in R version 2.14.2 (R Foundation for Statistical
Computing) and OpenEpi 2.3.1 (www.openepi.com/OE2.3/
Menu/OpenEpiMenu.htm).
Results
We identified 182 678 unique people who had been diagnosed
with atrial fibrillation on one or several occasions during the
3.5 years we studied. In total, these represented 1 845 906
hospital contacts. We excluded 73 591 patients who used
warfarin (or in a few cases, phenprocoumon) at index, 7078
who died in conjunction with the index hospital period, 1283
who had a diagnosis of mitral stenosis, and 7639 who had
undergone valvular surgery previously. Some patients were
excluded because of more than one criterion (web appendix,
table w2). After exclusions, 100 802 patients remained in the
study (table 1).
During a median follow-up of 1.2 years (range 0-3.5, total 139
504 years at risk), we identified 7221 patients who had a
thromboembolic stroke (annual stroke rate 5.2%, 95%
confidenceinterval5.1%to5.3%).Ischaemicstrokesweremore
common in women than in men (4264 strokes during 69 005
years at risk in women, and 2957 strokes during 70 594 years
atriskinmen,correspondingtoannualstrokeratesof6.2%and
4.2%respectively,P<0.0001),andwomenwithatrialfibrillation
had a 47% higher incidence of ischaemic stroke than men with
atrialfibrillation(univariablehazardratio1.47,95%confidence
interval 1.40 to 1.54). Visually, the difference in unadjusted
stroke incidence between men and women was larger in the
highest age groups (women v men: age <65 years, hazard ratio
1.09 (95% confidence interval 0.86 to 1.39, P=0.48); 65-74
years,1.04(0.91to1.20,P=0.53);≥75years,1.24(1.18to1.30,
P<0.0001); fig 1⇓).
The population attributable risk of female sex on stroke was
19.0% (95% confidence interval 17.0% to 20.1%)—that is,
patients would have had 19% fewer strokes if they were all
male. However, this univariable analysis did not adjust for an
increase of six years of mean age in women, compared with
men (81 v 75 years). Women also had more risk factors for
stroke than men (table 1). Women had a history of previous
stroke, dementia, frequent falls, and hypertension more often,
and men had a history of myocardial infarction, diabetes, liver
and renal problems, and alcohol abuse more often. Women
scored higher than men on the CHADS2 score (mean 2.3 v 1.9;
P<0.0001), which was partly due to the increased mean age in
women (age ≥75 years holds one point). When we stratified
patients according to CHADS2 scores, women had a higher
incidence of stroke than men in every group (fig 2⇓).
When we stratified low risk patients with CHADS2 scores of
0-1 according to the CHA2DS2-VASc score (which gives one
pointforfemalesex),wefoundthatwomendidnothavehigher
stroke incidence than men at CHA2DS2-VASc scores of 2 or
less (fig 3⇓). Patients with combinations of the “new” risk
factors (that is, those not included in CHADS2) did show stroke
ratesofabout4%annually,andthuswerenotreallyatlowrisk.
Amongpatientswithloneatrialfibrillation,definedasCHADS2
score 0 and age <65 years, the annual stroke rate tended to be
higher in women than in men but this difference was not
significant (0.7% v 0.5%, P=0.09; 31 strokes during 4626 years
at risk in women, 53 strokes during 11 677 years in men).
Drug treatments differed between the sexes. Because we
excluded patients who used warfarin at baseline, this excluded
group included more men than women. Warfarin was used by
30 364 (36%) women at index compared with 43 227 (44%) of
men. Women used β blockers and digoxin more often (rate
control drugs), whereas men used class I or class III
anti-arrhythmic drugs more often (rhythm control drugs).
After adjustment for differences in background characteristics,
an association remained between female sex and increased risk
ofischaemicstroke(hazardratio1.18,95%confidenceinterval
1.12 to 1.24). We found similar results when we included
acetylsalicylicacid,clopidogrel,andwarfarinastimedependent
covariates (1.14, 1.09 to 1.19; table 2⇓). Web appendix table
w3providesallriskestimatesofthedifferentcovariatesincluded
in the Cox model.
We found significant interactions with sex for age as a
continuousvariable,historyofstroke,vasculardisease,anduse
of diuretics. However, in all patients, except for narrowly
defined ischaemic stroke, the hazard ratio of ischaemic stroke
for sex remained above 1 (women v men), although not
significantly in some patients. The interaction with CHADS2
score was also significant, in which the difference in risk of
ischaemic stroke between the sexes seemed to diminish in the
presence of more comorbidities (fig 4⇓).
Discussion
In this large cohort study of more than 100 000 patients with
atrial fibrillation without warfarin treatment, unadjusted
incidenceofthromboembolicstrokewas47%higherinwomen
than in men. Although women had more risk factors for stroke
than men, they still had an 18% higher risk of stroke than men
even after adjustment.
In the Atrial Fibrillation Investigators’ meta-analysis of five
randomised trials in 1990, researchers found a 20% higher risk
in women than in men, although this analysis was not adjusted
for cofactors.
8 Larger differences in stroke risk between the
sexes were found in the Framingham study (hazard ratio 1.9),
Euroheartsurvey(1.8),andATRIAstudy(1.5),
1 4 16 17butthese
studiesweresubstantiallysmallerthanthepresentstudy.Indeed,
our study comprised over 7000 events of ischaemic stroke,
whereas the largest study investigating sex differences
previously, the ATRIA study, only had 369 events; none of the
other studies exceeded 100 events. Furthermore, our study
adjusted for 35 cofactors whereas the ATRIA and Framingham
studies only adjusted for seven and five cofactors, respectively.
The difference in risk between men and women was not the
sameinallsubgroups.AtanyCHADS2score,thepointestimate
of the relative stroke risk was higher in women than in men (fig
2). In multivariable analysis, we saw significant differences in
stroke risk in patients aged 75 years and older, and those with
CHADS2 scores lower than 4.
Sex had a significant interaction with the history of stroke.
Women with ischaemic stroke as the primary diagnosis had the
same stroke risk as men. A possible reason could be related to
the finding of a general increased threshold for warfarin
treatment in women. If women, after having a stroke, received
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3522 doi: 10.1136/bmj.e3522 (Published 31 May 2012) Page 3 of 10
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stroke rate between the sexes would probably be reduced. A
similartendencywasfoundinrelationtoahistoryofmyocardial
infarction. Such events could result in more standardised care
that ensures women receive the same level of care as men.
However,ourmultivariableanalysiswithexposuretowarfarin,
acetylsalicylic acid, and clopidogrel used as time dependent
covariates only reduced the estimated hazard ratio by a small
degree (from 1.18 to 1.14). Therefore, differences in medical
care probably had a marginal role in the observed differences
in stroke risk.
The absolute risk of atrial fibrillation related stroke in young
and otherwise healthy women (that is, aged <65 years and with
loneatrialfibrillation)waslowandonlynon-significantlyhigher
than in men (0.7% v 0.5%, P=0.09), indicating that female sex
intheabsenceofotherriskfactorsforstrokewouldnotindicate
a need for antithrombotic treatment. Nevertheless, healthy
women aged 65-74 years old had an annual stroke rate of 1.9%,
whichmaymeritanticoagulationandevaluationofsubtlerrisks
such as absolute levels of blood pressure, whether the patient
is aged closer to 65 years or to 75 years, and consideration of
otherriskfactorsbeyondthoseintheriskstratificationschemes
in order to decide on optimal treatment.
18 Eckman and
colleagues
19 suggested that treatment with new and “safer” oral
anticoagulantdrugscouldbeanoptionevenatthislowabsolute
risk, for which the threshold for treatment might be an annual
stroke rate of 0.9%. This observation is pertinent since aspirin
is less effective than new oral anticoagulant drugs for stroke
prevention and has a similar risk for major bleeding (and
intracranialhaemorrhage),
20andtheevidencesupportingaspirin
use for stroke prevention in atrial fibrillation is weak.
21
TheEuropeanSocietyofCardiology’sguidelines
10recommend
antithrombotic treatment for stroke prevention in all patients
with atrial fibrillation unless they are low risk (that is, age <65
years and with lone atrial fibrillation); therefore, young women
who have no risk factors would fall into this category, and the
present study supports this. Thus, patients with “female sex” as
theonlyriskfactor(butwhowouldstillhaveaCHA2DS2-VASc
score of 1 on that basis) would not need anticoagulation
treatment, if they fulfil the criteria of being younger than 65
years and have lone atrial fibrillation.
18 The central question is
to carefully define patients who are truly at low risk of atrial
fibrillationrelatedstroke,whichtheCHA2DS2-VAScscorecan
help with, as shown by performing best in identifying such
patients.
18
Many risk factors have continuous range of risk, even though
theyaretreateddichotomouslyinriskassessmentschemes.For
example, degrees of hypertension, diabetes, heart failure, and
vascular disease exist, and the disease (or risk factor) burden is
relevant. This is particularly evident with age, by starting to rise
from age 65 years onwards,
22 and rises by 1.5-fold per decade.
9
In some situations, there are suspicions about underlying or
incipientdiseasethatcouldinfluencestrokerisk,butyetwithout
definite diagnosis. Indeed, assessments of patient risk should
integratevariousfactors,suchasbleedingriskandpatientvalues
and preferences, to reach an informed decision about the
appropriate treatment.
23 In borderline situations, in which a
decisionaboutwhethertogiveanticoagulationtreatmentweighs
in the balance, we suggest that female sex should probably tip
the scale towards initiating treatment.
Limitations
Wehadnoinformationintheregistersaboutpatientswithatrial
fibrillation who were managed exclusively in primary care or
private care, nor did we have any information about those with
undiagnosed,silentparoxysmalatrialfibrillation.However,this
limitationisintrinsictoall similarstudies,includingthoseused
to validate the CHADS2 score.
15 The ATRIA study, which
comprised 17 974 selected individuals, only reported a
prevalence in the general population of 0.95%. Our nationwide
cohort study, comprising more than ten times the number of
patients, found that atrial fibrillation had a prevalence of 2% of
the Swedish population. Although undercoding of atrial
fibrillation in the register might still be possible, it is probably
muchlesssoinourstudy,comparedwithanyothermajorstudy
of atrial fibrillation done previously that we are aware of.
The patients in the study were derived from a Swedish hospital
basedcohort.Althoughpatientscouldalternatebetweenhospital
and primary care, it might be assumed that patients with atrial
fibrillationwhogotohospitalaresicker,inonewayortheother,
than patients who do not go to hospital. Thus, we do not know
whether our findings applied to patients managed exclusively
in primary care, or even to those with silent (sometimes as yet
undiagnosed)atrialfibrillation.Tosomeextent,theselimitations
are counterbalanced by the fact that our cohort study
consecutively included all patients with atrial fibrillation on a
nationwide scale for several years.
The Swedish hospital discharge register is subjected to annual
quality control to ascertain completeness of information, and
less than 1% of hospital periods lack a proper discharge record
with at least one principal diagnosis as cause for the care.
13 14
For some important diagnoses such as myocardial infarction
and heart failure, external validation of the diagnostic accuracy
is good.
24 25 For many other diagnoses, we know little about the
validityoftheregister,andsomecomorbiditiescouldhavebeen
under-reported (especially for hypertension), whereas
over-reporting was probably much rarer. Thus, patients might
have had more risk factors than we were aware of and could
adjust for, but again, this limitation is inherent in all forms of
registry studies.
In our study, women were older and had more risk factors for
stroke than men, and thus, residual confounding (that we were
unable to adjust for) might have been evident. Our only source
of information was medical registers, with limited information
about degree or severity of illness and about lifestyle factors
such as obesity, smoking, and drinking that could also affect
outcome. Also, our analysis did not account for
echocardiographicdata.Indeed,failuretoadjustforunderlying
differencesincofactorscouldhavegivenanexaggeratedpicture
of differences between the sexes. Other studies, which adjusted
for far fewer cofactors than ours, showed much larger
differences in stroke risk between men and women than our
study.
1 7 8 26 Also, observational studies have generally shown
larger differences than randomised trials.
1 4 7 8 17 26 27 The most
probablereasonisthatrandomisationevensoutsomedifferences
inbackgroundcharacteristicsmoreefficientlythanmultivariable
adjustments. The finding of a relatively small difference in risk
between the sexes found in our study therefore could have been
a result of our successful adjustment for many cofactors.
We selected patients for the study on the basis that they did not
usewarfarinatbaseline.However,morementhanwomen(44%
v 36%) were using warfarin. A higher threshold for
anticoagulation for women than for men could have resulted in
selectionbias.Womenwhodidnotreceivewarfarin,butperhaps
would have had it if the sexes were treated equally, naturally
carry an increased stroke risk. Thus, the consequence would
have been an exaggeration of the risk differences between men
and women.
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RESEARCHWhat is already known on this topic
Several studies have indicated that women with atrial fibrillation are at higher risk for ischaemic stroke than men, although other studies
found no such difference
With few other risk factors to consider, female sex might be important in making decisions regarding anticoagulation treatment
What this study adds
Women with atrial fibrillation have a moderately increased risk of stroke compared with men with atrial fibrillation
Women younger than 65 years and without other risk factors for stroke have the same low risk as men with the same characteristics,
and do not need anticoagulant treatment
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RESEARCHTables
Table 1| Baseline characteristics of study groups. Data are no (%) of patients unless stated otherwise
Women Men
50 667 (50.3) 50 135 (49.7) No (%)
Age (years)
80.9 (10.6) 74.7 (13.5) Mean (standard deviation)
83 78 Median
History of atrial fibrillation
31 469 (62) 30 905 (62) First ever diagnosis <7 days
Medical history more common in women
5265 (10) 1218 (2) Thyroid disease
6368 (13) 2990 (6) Frequent falls
3571 (7) 2444 (5) Dementia
1111 (2) 784 (2) Pulmonary embolism
Thromboembolism
8095 (16) 6625 (13) Ischaemic stroke*
3757 (7) 3130 (6) Other thromboembolism†
7169 (14) 5872(12) Anaemia
23 511 (46) 19 188 (38) Hypertension
17 644 (35) 15 491 (31) Heart failure
Medical history more common in men, bleeding
1015 (2) 1314 (3) Intracranial bleeding
3231 (6) 3229 (6) Other major bleeding
3272 (6) 3650 (7) Use of pacemaker
8423 (17) 9272 (18) Diabetes
3793 (7) 4393 (9) Emphysema or chronic obstructive pulmonary disease
Medical history more common in men, vascular disease
9224 (18) 11 104 (22) Myocardial infarction
2244 (4) 2699 (5) Other vascular disease‡
4385 (9) 7033 (14) Cancer within three years
561 (1) 809 (2) Platelet defects or coagulopathy
2331 (5) 3668 (7) Renal disease
541 (1) 870 (2) Liver disease
544 (1) 2715 (5) Alcohol index§
Stroke risk score (mean (standard deviation))
2.3 (1.4) 1.9 (1.4) CHADS2
4.4 (1.7) 3.0 (1.8) CHA2DS2-VASc
Use of antithrombotic drugs
32 044 (63) 28 874 (58) Acetylsalicylic acid only
1060 (2) 908 (2) Clopidogrel only
2063 (4) 3013 (6) Acetylsalicylic acid and clopidogrel
15 500 (31) 17 340 (35) None of the above
Use of other drugs
33 114 (65) 30 016 (60) β blockers
934 (2) 1249 (2) Class 1 anti-arrhythmic drugs
3257 (6) 4190 (8) Class 3 anti-arrhythmic drugs
2638 (5) 1862 (4) Verapamil or diltiazem
8871 (18) 7869 (16) Calcium blocker dihydropyridine
14 640 (29) 10 289 (21) Digoxin
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RESEARCHTable 1 (continued)
Women Men
31 898 (63) 24 528 (49) Diuretics
19 519 (39) 20 687 (41) Angiotensin converting enzyme inhibitors and angiotensin
receptor blockers
9717 (19) 13 282 (26) Statin
All comparisons between men and women were P<0.05, except for history of atrial fibrillation (P=0.13).
*Narrow definition: previous diagnosis of ischaemic stroke (ICD-10 code I63) as principal diagnosis only.
†Narrow definition: previous secondary diagnosis of ischaemic stroke (I63) or any diagnosis of unspecified stroke (I64), transient ischaemic attack (G45), or
peripheral emboli (I74).
‡Arterial disease without previous myocardial infarction (I65, I70-73).
§Diagnostic codes used by the Swedish Board of Health of Welfare since 1987 to report alcohol related mortality (web appendix, table w1).
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RESEARCHTable 2| Atrial fibrillation related stroke risk in women compared with men
P Hazard ratio (95% CI) Model
<0.001 1.47 (1.40 to 1.54) Univariable
<0.001 1.16 (1.11 to 1.22) Adjusted for age
<0.001 1.27 (1.21 to 1.33) Adjusted for CHADS2 score
<0.001 1.18 (1.12 to 1.24) Multivariable (intention to treat)
<0.001 1.18 (1.13 to 1.25) Multivariable (intention to treat), age modelled with cubic
spline
<0.001 1.14 (1.09 to 1.19) Multivariable with time dependent covariates*
Adjustments made for age, previous embolic event, heart failure, hypertension, diabetes, vascular disease, intracranial bleed, pacemaker, chronic obstructive
pulmonary disease, pulmonary embolism, thyroid disease, platelet defect or coagulopathy, anaemia, renal failure, liver disease, alcohol index, dementia, frequent
falls, cancer within three years, years since first diagnosis of atrial fibrillation, use of acetylsalicylic acid, clopidogrel, β blockers, class I anti-arrhythmic drugs, class
3 anti-arrhythmic drugs, verapamil or diltiazem, dihydropyridine calcium blocker, digoxin, diuretics, angiotensin converting enzyme inhibitors and angiotensin
receptor blockers, and statin.
*Warfarin was also included.
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RESEARCHFigures
Fig 1 Unadjusted incidence of stroke in relation to age. Cox regression with main and interaction terms for sex and age
group
Fig 2 Stroke rate in relation to CHADS2 score
Fig 3 Stroke rate in patients with CHADS2 score 0-1 in relation to CHA2DS2-VASc score
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RESEARCHFig 4 Risk of ischaemic stroke in women compared with men in relation to risk factors in CHADS2 and CHA2DS2-VASc
schemes. All interactions modelled within the multivariable primary Cox regression, except CHADS2 (in which only sex and
CHADS2 were included in the model). Interaction between sex and age was significant when age was included as a
continuous variable in the model
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